5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Zacks·1d ago
More News
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3% - Here's Why
Denali Therapeutics (NASDAQ:DNLI) Shares Up 11.3% - Still a Buy...
MarketBeat·13d ago
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has earned an average recommendation of "Buy" from the sixteen ratings firms that are covering the company, MarketBeat reports. One research...
MarketBeat·15d ago
Campbell & CO Investment Adviser LLC Purchases 74,066 Shares of Denali Therapeutics Inc. $DNLI
Campbell & CO Investment Adviser LLC raised its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 51.9% in the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·19d ago
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
Zacks·28d ago
3 Biotech Stocks With Major 2026 Catalysts
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Zacks·1mo ago
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have received an average rating of "Buy" from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. One...
MarketBeat·1mo ago
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given an average recommendation of "Buy" by the sixteen ratings firms that are currently covering the firm, MarketBeat...
MarketBeat·1mo ago
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI
Marex Group plc acquired a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·2mo ago
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI
Camber Capital Management LP cut its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 68.0% in the second quarter, according to its most recent Form 13F filing with the Securities...